Because the in vitro and in vivo galunisertib monotherapy data strongly suggested that galunisertib was able to modulate anti-tumor T cell immunity, we investigated whether galunisertib could synergize with PD-L1 checkpoint blockade and result in improved tumor regressions. The gene discussed is CD274; the disease is neoplasm.